Parents might one day give their children a weekly treatment with a nasal spray of virus enzymes to prevent them from getting a severe middle ear infection, based on results of a study done in mice by investigators from St. Jude Children’s Research Hospital and The Rockefeller University, in New York.
GlaxoSmithKline (GSK) announced that its new, novel topical antibiotic ALTARGO? (retapamulin ointment, 1%) received a positive opinion from the European Committee for Human Medicinal Products (CHMP) for the treatment of impetigo and infected small lacerations, abrasions or sutured wounds.
The Food and Drug Administration (FDA) and California’s Department of Health Services (CDHS) released a joint report on an extensive investigation into the causes of an E.coli O157:H7 outbreak last fall that was associated with contaminated Dole brand Baby Spinach and resulted in 205 confirmed illnesses and three deaths.
Using lysins, a protein from viruses that infect bacteria, scientists have developed a novel way to prevent kids from developing middle ear infections.
One in four teenagers who had meningitis during infancy will not pass any GCSE exams, reveals research published ahead of print in Archives of Disease in Childhood.
A small piece of DNA that helps bacteria commonly found in US meat and poultry resist several antibiotics has also been found in the plague bacillus Yersinia pestis, gene sequence researchers report.
Antibiotics are prescribed for approximately 82 percent of acute sinus infections and nearly 70 percent of chronic sinus infections, despite the fact that viruses are by far the most frequent cause of this condition, according to a report in the March issue of Archives of Otolaryngology — Head & Neck Surgery, one of the JAMA/Archives journals.
Understanding why other bacteria become resistant to antibiotics could hold the key to understanding why TB takes so long to cure, say researchers in a policy paper in PLoS Medicine.
Research by a team at the University of Cincinnati (UC) has helped in the discovery of a new way to fight antibiotic-resistant bacteria, responsible for preventing treatment of lung infections in patients with cystic fibrosis and life-threatening cases of pneumonia.
The U.S. Food and Drug Administration (FDA) approved Soliris (eculizumab), the first product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare type of blood disorder that can lead to disability and premature death. Soliris is classified as an Orphan Drug and is a new molecular entity containing an ingredient not previously marketed in the United States.